NRAS and neoplasm: Both Usp9x KD and G9 blocked anchorage-independent melanoma growth (Fig. 1g) and G9 dose-dependently inhibited melanoma growth in matrigel (Fig. 1h), with nM sensitivity against NRAS mutant cells (SK-Mel103; IC50 ∼300 nM), suggesting that Usp9x plays a role in tumour expansion, particularly in tumours with an NRAS mutation.